Compare BOC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | CCCC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.7M | 404.7M |
| IPO Year | 2010 | 2020 |
| Metric | BOC | CCCC |
|---|---|---|
| Price | $14.06 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 97.8K | ★ 2.3M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $114,376,348.00 | $35,947,000.00 |
| Revenue This Year | $5.79 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | 1.02 |
| 52 Week Low | $10.52 | $1.69 |
| 52 Week High | $15.22 | $5.17 |
| Indicator | BOC | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 58.78 |
| Support Level | $13.95 | $3.40 |
| Resistance Level | $14.71 | $4.60 |
| Average True Range (ATR) | 0.41 | 0.23 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 65.68 | 74.21 |
Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.